MX366196B - Polipeptidos diseñados de fenilalanina amonio liasa. - Google Patents

Polipeptidos diseñados de fenilalanina amonio liasa.

Info

Publication number
MX366196B
MX366196B MX2015014662A MX2015014662A MX366196B MX 366196 B MX366196 B MX 366196B MX 2015014662 A MX2015014662 A MX 2015014662A MX 2015014662 A MX2015014662 A MX 2015014662A MX 366196 B MX366196 B MX 366196B
Authority
MX
Mexico
Prior art keywords
polypeptides
engineered
phenylalanine ammonia
pal
ammonia lyase
Prior art date
Application number
MX2015014662A
Other languages
English (en)
Other versions
MX2015014662A (es
Inventor
Benjamin Mijts
Xiyun Zhang
Nicholas J Agard
Jonathan Vroom
W Huisman Gjalt
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of MX2015014662A publication Critical patent/MX2015014662A/es
Publication of MX366196B publication Critical patent/MX366196B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01005—Phenylalanine ammonia-lyase (4.3.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)

Abstract

La presente invención se refiere a polipéptidos diseñados de fenilalanina amonio liasa (PAL) y composiciones de los mismos, así como polinucleótidos que codifican a los polipéptidos de fenilalanina amonio-liasa (PAL); en algunas modalidades, los polipéptidos PAL diseñados son optimizados para proporcionar una mejor actividad catalítica, así como una reducción de la sensibilidad a la proteólisis y con mayor tolerancia a los niveles de pH ácido; en algunas modalidades los polipéptidos PAL diseñados están desinmunizados; la invención también se refiere al uso de las composiciones que comprenden los polipéptidos PAL diseñados con fines terapéuticos e industriales.
MX2015014662A 2013-04-18 2014-04-17 Polipeptidos diseñados de fenilalanina amonio liasa. MX366196B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361813586P 2013-04-18 2013-04-18
US201361897932P 2013-10-31 2013-10-31
PCT/US2014/034500 WO2014172541A2 (en) 2013-04-18 2014-04-17 Engineered phenylalanine ammonia lyase polypeptides

Publications (2)

Publication Number Publication Date
MX2015014662A MX2015014662A (es) 2016-03-03
MX366196B true MX366196B (es) 2019-07-01

Family

ID=51729192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014662A MX366196B (es) 2013-04-18 2014-04-17 Polipeptidos diseñados de fenilalanina amonio liasa.

Country Status (27)

Country Link
US (17) US9611468B2 (es)
EP (3) EP3521423B1 (es)
JP (5) JP6637410B2 (es)
KR (1) KR102218930B1 (es)
CN (2) CN105324483B (es)
AU (2) AU2014253900C1 (es)
CA (1) CA2909719C (es)
CY (1) CY1121891T1 (es)
DK (2) DK3521423T3 (es)
EA (1) EA034034B1 (es)
ES (2) ES2890955T3 (es)
HR (1) HRP20190928T1 (es)
HU (2) HUE043549T2 (es)
IL (1) IL242067B (es)
LT (1) LT2986722T (es)
MX (1) MX366196B (es)
MY (1) MY193198A (es)
NZ (1) NZ713396A (es)
PE (1) PE20151775A1 (es)
PH (1) PH12015502412A1 (es)
PL (1) PL2986722T3 (es)
PT (1) PT2986722T (es)
RS (1) RS58802B1 (es)
SG (1) SG11201508598YA (es)
SI (1) SI2986722T1 (es)
SM (1) SMT201900315T1 (es)
WO (1) WO2014172541A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366196B (es) 2013-04-18 2019-07-01 Codexis Inc Polipeptidos diseñados de fenilalanina amonio liasa.
HUE056444T2 (hu) * 2014-04-16 2022-02-28 Codexis Inc Génmódosított tirozin-ammónia-liáz
EP3294760B1 (en) 2015-05-13 2021-03-24 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
CN106636048A (zh) * 2016-12-14 2017-05-10 江南大学 一株酶活提高的苯丙氨酸脱氨酶突变体
CN106755160B (zh) * 2017-01-17 2019-08-02 湖州颐辉生物科技有限公司 一种组氨酸解氨酶及其用途
WO2018148633A1 (en) * 2017-02-13 2018-08-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
JP7320495B2 (ja) * 2017-05-27 2023-08-03 エンズィマスター（ニンボー）バイオ－エンジニアリング カンパニー リミテッド 操作されたアルドラーゼポリペプチドおよびその使用
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
CN112672989A (zh) * 2018-07-12 2021-04-16 科德克希思公司 工程化苯丙氨酸氨裂合酶多肽
KR20210084590A (ko) * 2018-10-29 2021-07-07 코덱시스, 인코포레이티드 조작된 dna 중합효소 변이체
EP3893860A4 (en) * 2018-12-14 2023-03-29 Codexis, Inc. ENGINEERED TYROSINE AMMONIA LYASE
EP4107281A4 (en) * 2020-02-19 2024-08-14 Trustees of Tufts College PROCESS FOR PRODUCING AMINO ACID-AMMONIAC LYASE ENZYMES AND ENZYMES OBTAINED THEREFROM
JP2023518184A (ja) 2020-03-20 2023-04-28 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を軽減するように遺伝子改変された微生物
WO2022146718A1 (en) * 2020-12-31 2022-07-07 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
TW202313969A (zh) * 2021-05-21 2023-04-01 美商克迪科思股份有限公司 經工程化的甲硫胺酸γ解離酶變異體
CN114015636B (zh) * 2021-12-08 2023-09-29 天地壹号饮料股份有限公司 重组醋酸菌及其制备方法和应用
CN114457151B (zh) * 2022-01-27 2024-06-11 宁夏医科大学总医院 一种用于检测苯丙氨酸羟化酶基因突变的检测试剂盒及其检测方法
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN115518691B (zh) * 2022-10-14 2023-11-21 天津大学 一种具有类漆酶活性的人工酶及制备方法和应用
CN115873837A (zh) * 2022-11-18 2023-03-31 安徽盈科生物科技有限公司 高表达的新型的苯丙氨酸解氨酶
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
WO2025063255A1 (ja) * 2023-09-19 2025-03-27 積水化学工業株式会社 アンモニアリアーゼおよびその用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US603344A (en) 1898-05-03 Trough for well-curbs
US753653A (en) 1903-09-14 1904-03-01 American Car & Foundry Co Hopper-bottom car.
DK75593D0 (es) * 1993-06-25 1993-06-25 Novo Nordisk As
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
EP0765394B1 (en) 1994-06-03 2001-10-04 Novo Nordisk Biotech, Inc. Purified myceliophthora laccases and nucleic acids encoding same
AU2705895A (en) 1994-06-30 1996-01-25 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP1007732B1 (en) 1997-01-17 2006-07-26 Maxygen, Inc. EVOLUTION OF procaryotic WHOLE CELLS BY RECURSIVE SEQUENCE RECOMBINATION
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
AU3210100A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
EP1272967A2 (en) 2000-03-30 2003-01-08 Maxygen, Inc. In silico cross-over site selection
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
EP1493027B1 (en) 2002-03-01 2014-10-15 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional bio-molecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
JP4851687B2 (ja) 2002-03-09 2012-01-11 マキシジェン， インコーポレイテッド 定向進化のための交叉点の最適化
US8003356B2 (en) 2004-04-20 2011-08-23 E. I. Du Pont De Nemours And Company Methods for the preparation of para-hydroxycinnamic acid and cinnamic acid at alkaline pH
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
US20090038023A1 (en) 2005-03-10 2009-02-05 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US20090011400A1 (en) * 2006-12-01 2009-01-08 The Salk Institute for Biological Studies and The Regents of the University of California Substrate switched ammonia lyases and mutases
US7560263B2 (en) * 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
CA2726850C (en) 2008-06-13 2015-06-02 Codexis, Inc. Method of synthesizing polynucleotide variants
CN106834261B (zh) * 2010-02-04 2022-02-18 生物马林药物股份有限公司 原核苯丙氨酸解氨酶变异体的组合物以及利用其组合物的方法
MX2013004944A (es) 2010-11-05 2013-06-28 Basf Plant Science Co Gmbh Metodo para aumentar el rendimiento y la produccion de quimicos finos en las plantas.
WO2012122333A1 (en) 2011-03-08 2012-09-13 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Microbial conversion of glucose to styrene and its derivatives
US20130005012A1 (en) 2011-06-23 2013-01-03 Phytogene, Inc. Enzymatic system for monomer synthesis
MX366196B (es) 2013-04-18 2019-07-01 Codexis Inc Polipeptidos diseñados de fenilalanina amonio liasa.

Also Published As

Publication number Publication date
BR112015026160A2 (pt) 2017-10-10
PL2986722T3 (pl) 2019-10-31
US20200032233A1 (en) 2020-01-30
DK2986722T3 (da) 2019-05-13
US20200199566A1 (en) 2020-06-25
US20200032234A1 (en) 2020-01-30
US10717974B2 (en) 2020-07-21
EP2986722B1 (en) 2019-04-03
US11401515B2 (en) 2022-08-02
US10294468B2 (en) 2019-05-21
AU2019272057B2 (en) 2021-05-27
US10941391B2 (en) 2021-03-09
US20170191050A1 (en) 2017-07-06
CN109486803B (zh) 2022-10-25
US20180037880A1 (en) 2018-02-08
US10494623B2 (en) 2019-12-03
PT2986722T (pt) 2019-06-21
US20200032236A1 (en) 2020-01-30
US10358639B2 (en) 2019-07-23
US20200040325A1 (en) 2020-02-06
JP2016516428A (ja) 2016-06-09
EA201591995A1 (ru) 2016-04-29
US11913045B2 (en) 2024-02-27
US20190055535A1 (en) 2019-02-21
LT2986722T (lt) 2019-09-10
EP3971288A1 (en) 2022-03-23
RS58802B1 (sr) 2019-07-31
PH12015502412B1 (en) 2016-02-22
JP2020185016A (ja) 2020-11-19
US10487319B2 (en) 2019-11-26
CN105324483A (zh) 2016-02-10
US11130947B2 (en) 2021-09-28
US20140314843A1 (en) 2014-10-23
JP2018166524A (ja) 2018-11-01
EP2986722A4 (en) 2017-02-22
MX2015014662A (es) 2016-03-03
US20190040377A1 (en) 2019-02-07
US20210222146A1 (en) 2021-07-22
EP3521423A1 (en) 2019-08-07
US20190055536A1 (en) 2019-02-21
JP6637410B2 (ja) 2020-01-29
US20180016568A1 (en) 2018-01-18
US20200032235A1 (en) 2020-01-30
CN109486803A (zh) 2019-03-19
SMT201900315T1 (it) 2019-07-11
US10640759B2 (en) 2020-05-05
CA2909719A1 (en) 2014-10-23
MY193198A (en) 2022-09-26
IL242067B (en) 2018-03-29
US10160963B2 (en) 2018-12-25
EP2986722A2 (en) 2016-02-24
CY1121891T1 (el) 2020-10-14
US20200399627A1 (en) 2020-12-24
SI2986722T1 (sl) 2019-07-31
CA2909719C (en) 2022-09-27
AU2014253900C1 (en) 2020-04-02
US9611468B2 (en) 2017-04-04
AU2019272057A1 (en) 2019-12-19
WO2014172541A2 (en) 2014-10-23
ES2890955T3 (es) 2022-01-25
HRP20190928T1 (hr) 2019-07-26
KR20150143816A (ko) 2015-12-23
AU2014253900A1 (en) 2015-11-12
WO2014172541A3 (en) 2015-02-19
EA034034B1 (ru) 2019-12-20
JP2022183356A (ja) 2022-12-08
US10144924B2 (en) 2018-12-04
AU2014253900B2 (en) 2019-09-19
PE20151775A1 (es) 2015-12-02
DK3521423T3 (da) 2021-09-06
US20200231959A1 (en) 2020-07-23
NZ713396A (en) 2020-06-26
HUE043549T2 (hu) 2019-08-28
US11136571B2 (en) 2021-10-05
ES2729048T3 (es) 2019-10-30
US10870843B2 (en) 2020-12-22
CN105324483B (zh) 2018-11-30
SG11201508598YA (en) 2015-11-27
US20190241882A1 (en) 2019-08-08
EP3521423B1 (en) 2021-07-21
JP7129715B2 (ja) 2022-09-02
PH12015502412A1 (en) 2016-02-22
JP2020185017A (ja) 2020-11-19
HUE055899T2 (hu) 2022-01-28
KR102218930B1 (ko) 2021-02-23
US10975367B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
PH12015502412A1 (en) Engineered phenylalanine ammonia lyase polypeptides
PH12018501839A1 (en) St2l antagonists and methods of use
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX342920B (es) Metodo para purificar polipeptidos o inmunoconjugados activos.
EP2926460A4 (en) SYSTEMS AND METHODS FOR ENCODING AND DECODING NON-SYSTEMATIC IRA CODES WITH IRREGULAR CONTROL
IL240030A0 (en) 2-aza-bicyclo[1.2.2]heptane-3-carboxylic acid (benzyl-cyano-methyl)-modified amides inhibitors of cathepsin c
UA115231C2 (uk) Сполуки імідазопіролідинонів
EA201790876A1 (ru) Способ контроля, предотвращения или лечения кровотечения
UA117218C2 (uk) Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
MX360056B (es) Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
PH12019501705A1 (en) Engineered phenylalanine ammonia lyase polypeptides
PH12016500598A1 (en) Protoxin-ii variants and methods of use
PH12015501627A1 (en) Kv1.3 antagonists and methods of use
PH12013501205A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
EA201991896A1 (ru) Сконструированные полипептиды фенилаланин-аммиаклиазы
UA113976C2 (xx) Композиція солі n-(8-(2-гідроксибензоїл)аміно)каприлової кислоти і пептиду glp-1
HK1223560A1 (zh) 人造血紅素結合組合物及其用途
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration